Thermo Fisher Scientific (TMO), What Is Behind Its Latest Move?
Thermo Fisher Scientific (TMO) moved back into focus after its third quarter on 21 October 2026, as higher sales, earnings and raised full year guidance drew close attention from investors.
The latest results landed after a strong run. Thermo Fisher Scientific’s share price has gained 19.05% over the past 90 days and 14.18% year to date. Its 1 year total shareholder return of 18.71% signals momentum that has been building rather than fading.
Review how Thermo Fisher Scientific’s earnings beat compares with other lab and biopharma suppliers by exploring our handpicked 36 healthcare AI stocks positioned at the intersection of healthcare and AI.
Thermo Fisher Scientific’s recent climb reflects both stronger quarterly delivery and a reset in expectations. Are investors now paying mainly for upgraded fundamentals, or for a brighter story around them?
Most Popular Narrative: 1% Undervalued
Thermo Fisher Scientific’s most followed narrative places fair value at $686.64, just above the last close of $676.54, which frames the recent rally as largely in line with fundamentals rather than detached from them.
Improving funding and higher activity in pharma and biotech, which represent about 60% of Thermo Fisher Scientific revenue and have delivered several quarters of sequentially stronger organic growth, are expected to support continued demand for research reagents, clinical trial services and bioproduction, with a direct effect on revenue growth and operating leverage.
See why 96 investors see Thermo Fisher Scientific as 1% undervalued.
Result: Fair Value of $686.64 (ABOUT RIGHT)
Still, the Thermo Fisher Scientific story depends heavily on pharma and biotech funding remaining supportive, while any weaker execution on portfolio shifts could challenge that fair value view.
Find out about the key risks to this Thermo Fisher Scientific narrative.
Another View: Thermo Fisher Scientific On Earnings Multiples
While the fair value narrative points to Thermo Fisher Scientific as roughly 1% undervalued, the P/E lens is less relaxed. TMO trades on 35.4x earnings, above its own fair ratio of 34.4x, which suggests limited margin for error if sentiment cools.
Against peers, the picture changes. The same 35.4x P/E sits below the peer average of 38.6x and under the Global Life Sciences mark of 36.7x. That mix of slightly rich versus the fair ratio but cheaper than similar stocks raises a simple question: Is this paying up for quality or paying forward too much optimism?
See what the numbers say about this price in our valuation breakdown, then compare it with other tools investors use to frame Thermo Fisher Scientific risk and opportunity. See what the numbers say about this price — find out in our valuation breakdown.
To see how that valuation stacks up against the wider Life Sciences space, review the current industry P/E snapshot for Thermo Fisher Scientific.
Next Steps
Sentiment around Thermo Fisher Scientific looks balanced rather than euphoric, which is exactly when independent work matters most. Move quickly, stress test the bullish and cautious angles, and then anchor your own stance with the 2 key rewards and 1 important warning sign
Looking for more Thermo Fisher Scientific sized ideas?
If you stop your research here, you risk missing other businesses with strong income, cash flows and balance sheets that could fit your portfolio even better.
- Target stability and financial strength by scanning a list of solid balance sheet and fundamentals (26 results) that can handle stress without sacrificing fundamentals.
- Hunt for mispriced opportunities by reviewing a 29 high quality undervalued stocks that combine quality operations with prices that have not yet fully reflected it.
- Stack potential income and resilience by checking a 6 dividend fortresses built around higher yields and durable cash coverage.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com